Development of Novel Evaluation Systems and Treatment Strategies for Obesity/Diabetes-related Cognitive Impairment through Targeting TREM2
Description: Genome-wide association studies previously suggested that a cell surface receptor TREM2 is implicated in the development and progression of dementia. The present study provided the first evidence that serum levels of TREM2 may be a novel marker of the diabetes-related cognitive impairment, by the cross-sectional approach using a database of the multicenter prospective observational cohort consisting of patients with obesity and/or type 2 diabetes. We further demonstrated that omega-3 polyunsaturated fatty acids, medications for metabolic diseases, exhibit the novel anti-inflammatory effects through SIRT1 pathways on the activated mouse microglia. These findings could contribute to developing novel predictive markers and effective therapeutic strategies for obesity/diabetes-related dementia.
Amount: ¥4,680,000
Funding type: research
Funder scheme: Grant-in-Aid for Scientific Research (C)
Start date: 2016-04-01
End date: 2019-03-31
Investigator: Masashi Tanaka
Institution: Health Science University(2018)Department of Clinical Research, National Hospital Organization Kyoto Medical Center(2016-2017)
Subfield: Neurology
Field: Neuroscience
Domain: Life Sciences
Funded outputs count: 12
Funder award ID: 16K09276
OpenAlex ID: G4676400767